← Back to Search

Survivor & Provider Activation for Colorectal Cancer Screening (ASPIRES Trial)

N/A

Waitlist Available

Led By Tara O Henderson, MD, MPH

Research Sponsored by University of Chicago

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Have no family history of colorectal cancer

Were treated with radiation to the abdomen, pelvis, spine, or total body irradiation

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 14 months

Awards & highlights

ASPIRES Trial Summary

This trial is testing different ways to get high-risk cancer survivors to get screened for colorectal cancer at the recommended age.

Who is the study for?

This trial is for high-risk cancer survivors without a family history of colorectal cancer, who were treated with certain types of radiation, and haven't had recent colorectal screenings. Participants must have a smartphone, be part of the Childhood Cancer Survivor Study, speak English, and live in the U.S.Check my eligibility

What is being tested?

The ASPIRES study is testing different methods to motivate these survivors to undergo colorectal cancer screening. It compares no intervention (control) with strategies aimed at activating patients directly or through their primary care providers.See study design

What are the potential side effects?

Since this trial focuses on activation methods rather than medical treatments or drugs, there are no direct side effects associated with the interventions being tested.

ASPIRES Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My family has no history of colorectal cancer.

Select...

I have received radiation therapy to my abdomen, pelvis, spine, or whole body.

Select...

I have never had colorectal cancer.

ASPIRES Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 14 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~14 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 14 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Proportion of patients who report completing a colonoscopy or Cologuard test (Cologuard test plus colonoscopy if Cologuard is positive) within 12 months of randomization

Secondary outcome measures

Cost and Cost-Effectiveness Analysis

Interventional procedure

Potential barriers and facilitators to the uptake of the intervention at both the patient and provider level as measured by CFIR questions

+1 more

ASPIRES Trial Design

3Treatment groups

Experimental Treatment

Group I: Group1: Control (C)Experimental Treatment1 Intervention

Electronic educational materials (C).

Group II: Group 3: Patient Activation and PCP Activation (PA + PCP)Experimental Treatment3 Interventions

C + PA + PCP activation (PA+PCP) with physician materials about colorectal cancer risk in this population

Group III: Group 2: Patient Activation (PA)Experimental Treatment2 Interventions

C + patient activation (PA) consisting of interactive tailored text messages with links to videos and resources

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Control

2011

Completed Phase 4

~15780

Patient activation

2019

N/A

~320

0 / 3Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of ChicagoLead Sponsor

1,002 Previous Clinical Trials

817,535 Total Patients Enrolled

National Cancer Institute (NCI)NIH

13,657 Previous Clinical Trials

40,933,352 Total Patients Enrolled

St. Jude Children's Research HospitalOTHER

427 Previous Clinical Trials

5,306,262 Total Patients Enrolled

Media Library

Patient activation Clinical Trial Eligibility Overview. Trial Name: NCT05084833 — N/A

Colorectal Cancer Research Study Groups: Group1: Control (C), Group 2: Patient Activation (PA), Group 3: Patient Activation and PCP Activation (PA + PCP)

Colorectal Cancer Clinical Trial 2023: Patient activation Highlights & Side Effects. Trial Name: NCT05084833 — N/A

Patient activation 2023 Treatment Timeline for Medical Study. Trial Name: NCT05084833 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this research initiative currently open to new participants?

"This investigation, which was initially posted on February 14th 2022 and last modified one day later, is not currently recruiting patients. Nevertheless, 1069 other clinical trials are presently in search of candidates."

Answered by AI

Recent research and studies

BMC Health Services ResearchJournal

Implementing a Mhealth Intervention to Increase Colorectal Cancer Screening Among High-risk Cancer Survivors Treated with Radiotherapy in the Childhood Cancer Survivor Study (CCSS)

Henderson, Tara O., Jenna K. Bardwell, Chaya S. Moskowitz, Aaron McDonald, Chris Vukadinovich, Helen Lam, Michael Curry, et al.. 2022. “Implementing a Mhealth Intervention to Increase Colorectal Cancer Screening Among High-risk Cancer Survivors Treated with Radiotherapy in the Childhood Cancer Survivor Study (CCSS)”. BMC Health Services Research. Springer Science and Business Media LLC. doi:10.1186/s12913-022-08082-3.

clinicaltrials.govStudy

ASPIRES (Activating Cancer Survivors and Their Primary Care Providers to Increase Colorectal Cancer Screening) Study

Tara Henderson 2022. "ASPIRES (Activating Cancer Survivors and Their Primary Care Providers to Increase Colorectal Cancer Screening) Study". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05084833.